Free Trial

Denali Therapeutics (DNLI) Stock Price, News & Analysis

Denali Therapeutics logo
$14.70 -0.21 (-1.38%)
Closing price 07/3/2025 03:08 PM Eastern
Extended Trading
$14.69 -0.01 (-0.03%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Denali Therapeutics Stock (NASDAQ:DNLI)

Key Stats

Today's Range
$14.67
$15.00
50-Day Range
$13.04
$16.65
52-Week Range
$10.57
$33.33
Volume
613,309 shs
Average Volume
1.13 million shs
Market Capitalization
$2.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.71
Consensus Rating
Buy

Company Overview

Denali Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

DNLI MarketRank™: 

Denali Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 292nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Denali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Denali Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Denali Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Denali Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Denali Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Denali Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Denali Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.50% of the float of Denali Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Denali Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Denali Therapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving.
  • Dividend Yield

    Denali Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Denali Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.50% of the float of Denali Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Denali Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Denali Therapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving.
  • News Sentiment

    Denali Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Denali Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Denali Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.50% of the stock of Denali Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Denali Therapeutics' insider trading history.
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
See More Headlines

DNLI Stock Analysis - Frequently Asked Questions

Denali Therapeutics' stock was trading at $20.38 at the beginning of 2025. Since then, DNLI shares have decreased by 27.9% and is now trading at $14.6950.

Denali Therapeutics Inc. (NASDAQ:DNLI) announced its earnings results on Tuesday, May, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.07.

Denali Therapeutics (DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/06/2025
Today
7/04/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
430
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$33.71
High Stock Price Target
$45.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+129.4%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$422.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$330.53 million
Price / Cash Flow
N/A
Book Value
$8.53 per share
Price / Book
1.72

Miscellaneous

Free Float
127,117,000
Market Cap
$2.13 billion
Optionable
Optionable
Beta
1.33

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:DNLI) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners